Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATOS

ATOS - Atossa Genetics Inc Stock Price, Fair Value and News

1.02USD+0.01 (+0.99%)Market Closed
Watchlist

Market Summary

USD1.02+0.01
Market Closed
0.99%

ATOS Stock Price

View Fullscreen

ATOS RSI Chart

ATOS Valuation

Market Cap

127.8M

Price/Earnings (Trailing)

-4.28

Price/Sales (Trailing)

1.5K

EV/EBITDA

-1.13

Price/Free Cashflow

-6.42

ATOS Price/Sales (Trailing)

ATOS Profitability

Operating Margin

1752.83%

EBT Margin

-35245.40%

Return on Equity

-30.36%

Return on Assets

-29.33%

Free Cashflow Yield

-15.58%

ATOS Fundamentals

ATOS Revenue

Revenue (TTM)

84.6K

ATOS Earnings

Earnings (TTM)

-29.8M

Earnings Growth (Yr)

22.24%

Earnings Growth (Qtr)

36.63%

Breaking Down ATOS Revenue

Last 7 days

7.5%

Last 30 days

11.0%

Last 90 days

48.5%

Trailing 12 Months

39.1%

How does ATOS drawdown profile look like?

ATOS Financial Health

Current Ratio

28.35

ATOS Investor Care

Buy Backs (1Y)

1.04%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20150000
2014474.0K157.8K84.6K0
2013609.8K712.8K683.8K632.6K
2012000481.8K
20110000

Tracking the Latest Insider Buys and Sells of Atossa Genetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 15, 2023
weaver gregory l
sold
-32,500
0.65
-50,000
former evp, cfo, & director
Jun 20, 2023
weaver gregory l
bought
48,500
0.97
50,000
evp & cfo
Jul 02, 2021
weaver gregory l
acquired
365,337
2.2198
164,581
-
Jul 02, 2021
weaver gregory l
sold
-599,833
5.58
-107,497
-
Jul 02, 2021
weaver gregory l
sold (taxes)
-365,338
6.4
-57,084
-

1–5 of 5

Which funds bought or sold ATOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
246
1,506
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
29.27
139,000
395,000
0.03%
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-12,743
-
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
653
4,008
-%
Feb 14, 2024
VANGUARD GROUP INC
unchanged
-
814,466
4,994,640
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-55.67
-
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
reduced
-79.76
-25,214
8,043
-%
Feb 14, 2024
STATE STREET CORP
unchanged
-
62,604
383,918
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
reduced
-11.85
5,133
101,419
-%

1–10 of 43

Are Funds Buying or Selling ATOS?

Are funds buying ATOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATOS
No. of Funds

Unveiling Atossa Genetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
4.50%
5,697,536
SC 13G/A
Jul 08, 2022
blackrock inc.
2.8%
3,588,683
SC 13G
Feb 14, 2022
cvi investments, inc.
5.8%
7,762,500
SC 13G/A
Feb 09, 2022
vanguard group inc
5.51%
6,970,850
SC 13G
Feb 04, 2022
blackrock inc.
7.5%
9,539,593
SC 13G
Jan 13, 2022
empery asset management, lp
1.03%
1,312,500
SC 13G/A
Jan 15, 2021
cvi investments, inc.
-
3,800,000
SC 13G
Jan 15, 2021
intracoastal capital, llc
4.99%
3,749,923
SC 13G
Jan 15, 2021
cvi investments, inc.
-
2,304,289
SC 13G/A
Jan 14, 2021
empery asset management, lp
5.32%
3,800,000
SC 13G

Recent SEC filings of Atossa Genetics Inc

View All Filings
Date Filed Form Type Document
Nov 17, 2023
4
Insider Trading
Nov 15, 2023
4/A
Insider Trading
Nov 15, 2023
4
Insider Trading
Nov 15, 2023
3
Insider Trading

Peers (Alternatives to Atossa Genetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Atossa Genetics Inc News

Latest updates
Defense World27 hours ago
The Business Journals16 months ago

Atossa Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2015Q42015Q32015Q22015Q12014Q42014Q32014Q22014Q12013Q42013Q32013Q22013Q12012Q42012Q32012Q22012Q12011Q4
Revenue-100.0%-772,2442,694,1571,873,268938,3473,4269,87524,12447,21376,597326,078182,67098,456105,576223,09754,713-
Cost Of Revenue-646.4%-1,712,327313,406------30,95725,938222,16066,4645,7609,00017,7883,1975,164
Gross Profit-392.4%-1,341,871458,838--2,7133,4269,87524,124-133,69050,659103,918116,20692,69690,499205,30927,709-95,690
Interest Expenses----1,78413,4261511,443749-1.003527.002247,7562,4461,613-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-6.1%10210811612412713413714114314614143.0011.0010.0012.0014.0017.0019.0021.0012.0014.00
  Current Assets-7.9%98.0010611111812313313714114314614143.0011.0010.0012.0014.0016.0018.0021.0012.0014.00
    Cash Equivalents-5.4%94.0099.0010411111712613113614014213840.009.007.009.0013.0015.0017.0020.0010.0013.00
  Net PPE--------0.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-1.0%3.003.003.006.003.004.002.003.002.006.0011.0016.002.002.001.001.002.001.002.003.00-
  Current Liabilities-1.0%3.003.003.006.003.004.002.003.002.002.001.0016.002.002.001.001.002.001.001.003.004.00
Shareholder's Equity-6.3%98.0010511311812413013513814114414027.0010.008.0011.0013.0015.0018.0019.009.0011.00
  Retained Earnings-3.6%-178-172-162-156-148-140-134-129-124-119-112-111-104-100-97.02-94.07-91.45-88.17-80.90-76.83-74.75
  Additional Paid-In Capital0.4%25525425225124924824624424224022913011210710610510410398.0082.0081.00
Shares Outstanding-0.9%12512712712712712712712711412293.0048.009.00--------
Float------138---796---35.00---23.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations13.0%-3,883-4,465-7,022-4,523-5,410-5,949-4,878-3,665-3,062-5,337-4,408-3,432-2,678-2,229-3,229-2,708-1,768-2,502-2,148-2,443-2,298
Cashflow From Investing92.3%-1.00-13.00--2,008-2,706--13.00--9.00--367*-2.76-------56.46-2.96
Cashflow From Financing-Infinity%-1,475------1.0067910,196102,42833,8804,324-----11,337--

ATOS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 4,467$ 5,160$ 11,680$ 10,097
General and administrative3,0013,04510,6789,456
Total operating expenses7,4688,20522,35819,553
Operating loss(7,468)(8,205)(22,358)(19,553)
Impairment charge on investment in equity securities00(2,990)0
Interest income1,2741943,107207
Other expense, net(35)0(99)(123)
Loss before income taxes(6,229)(8,011)(22,340)(19,469)
Income taxes0000
Net loss(6,229)(8,011)(22,340)(19,469)
Foreign currency translation adjustment0(54)0(54)
Comprehensive loss$ (6,229)$ (8,065)$ (22,340)$ (19,523)
Loss per share of common stock - basic and diluted (in dollars per share)$ (0.05)$ (0.06)$ (0.18)$ (0.15)
Weighted average shares outstanding - basic and diluted (in shares)125,793126,624126,344126,624

ATOS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 94,031$ 110,890
Restricted cash110110
Prepaid expenses3,4724,031
Research and development rebate receivable28743
Other current assets72,423
Total current assets97,648118,197
Investment in equity securities1,7104,700
Other assets2,337635
Total Assets101,695123,532
Current liabilities  
Accounts payable7182,965
Accrued expenses1,2611,059
Payroll liabilities1,4441,525
Other current liabilities2119
Total current liabilities3,4445,568
Total Liabilities3,4445,568
Commitments and contingencies (Note 15)
Stockholders' equity  
Series B convertible preferred stock - $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock - $0.18 par value; 175,000 shares authorized; 125,304 and 126,624 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively22,79222,792
Additional paid-in capital - common stock254,886250,784
Treasury stock, at cost; 1,320 and 0 shares of common stock at September 30, 2023 and December 31, 2022, respectively(1,475)0
Accumulated deficit(178,534)(156,194)
Total Stockholders' Equity98,251117,964
Total Liabilities and Stockholders' Equity101,695123,532
Series B Preferred Stock [Member]  
Stockholders' equity  
Additional paid-in capital - Series B convertible preferred stock$ 582$ 582
ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEatossatherapeutics.com
 EMPLOYEES11

Atossa Genetics Inc Frequently Asked Questions


What is the ticker symbol for Atossa Genetics Inc? What does ATOS stand for in stocks?

ATOS is the stock ticker symbol of Atossa Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atossa Genetics Inc (ATOS)?

As of Thu Feb 22 2024, market cap of Atossa Genetics Inc is 127.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATOS stock?

You can check ATOS's fair value in chart for subscribers.

What is the fair value of ATOS stock?

You can check ATOS's fair value in chart for subscribers. The fair value of Atossa Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atossa Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atossa Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether ATOS is over valued or under valued. Whether Atossa Genetics Inc is cheap or expensive depends on the assumptions which impact Atossa Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATOS.

What is Atossa Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ATOS's PE ratio (Price to Earnings) is -4.28 and Price to Sales (PS) ratio is 1.45 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATOS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Atossa Genetics Inc's stock?

In the past 10 years, Atossa Genetics Inc has provided -0.454 (multiply by 100 for percentage) rate of return.